Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

Simcere Pharmaceutical Group Limited entered into an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.